Anti-GFAP Antibody, clone 2E8, ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 2E8 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Glial fibrilary acidic protein (GFAP). It targets an epitope with in 11 amino acids from the C-terminal region.
• Immunogen: KLH-conjugated linear peptide corresponding to 11 amino acids from the C-terminal region of human Glial fibrilary acidic protein (GFAP).
• Application: Anti-GFAP, clone 2E8, ZooMAb, Cat. No. ZRB2383, is a recombinant Rabbit Monoclonal Antibody that specifically targets Glial fibrillary acidic protein (GFAP) and has been tested for use in Immunocytochemistry, Immunohistochemistry (Paraffin), Immunfluorescence, and Western Blotting.
• Target description: Glial fibrillary acidic protein (UniProt: P14136; also known as GFAP) is encoded by the GFAP gene (Gene ID: 2670) in human. GFAP is a class-III intermediate filament that serves as a cell-specific marker that can distinguish astrocytes from other glial cells. GFAP is not detected outside the central nervous system. It is expressed in cells that lack fibronectin. GFAP is a good marker of astroglial injury where its levels are consistently upregulated. GFAP levels are also shown to be upregulated with age in rodents and humans. Hence, it can serve as a surrogate marker of aging in the brain. GFAP has a relatively slow metabolic turnover rate, which is consistent with its structural role. GFAP is composed of three distinct regions: an N-terminal head region, a central ROD region, and a C-terminal tail region. The ROD regions are highly conserved among intermediate filament proteins. However, the size and amino acid sequences of the head and tail regions can vary widely. Three different isoforms of GFAP have been described that are produced by alternative splicing. Mutations in GFAP gene are known to cause Alexander disease that is characterized by progressive failure of central myelination, usually leading to death within the first decade. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 30 μg/mL after reconstitution at 25 μL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.